In a quarterly note that reads more like a roadmap than a victory lap, Surgery Partners, Inc. (NASDAQ: SGRY) handed in a Q1 2026 report that headlines revenue growth, but keeps the net earnings question open. The company posted revenue of $810.9 million, up 4.5% from a year earlier, with same-facility revenues rising about 4.4% and revenue per case up 3.8%. The flip side: a net loss of $35.9 million for the quarter, implying a negative EPS despite robust top-line growth. The company also reaffirmed its revenue forecast for 2026—$3.35 billion to $3.45 billion—with Adjusted EBITDA of at least $530 million. Ticker in the deck, again: SGRY.

First Quarter 2026 Highlights

• Revenue: $810.9 million, up 4.5% year over year
• Same-facility revenues: up 4.4%
• Revenue per case: up 3.8%
• Same-facility cases: up 0.6%
• Net loss: $35.9 million for the quarter
• Adjusted EBITDA: $102.3 million, versus $103.9 million in Q1 2025 (a modest step down)

The numbers suggest a company growing its top line with some efficiency headwinds that keep the bottom line in the red for the quarter. In investor terms, this translates to EPS that isn’t positive for the quarter even as the business shows underlying volume and pricing momentum. There’s no formal earnings surprise event here—the results largely align with ongoing guidance and the company’s narrative about improving free cash flow and asset deployment.

Liquidity and balance sheet posture remain a focus: cash and cash equivalents stood at $182.3 million, with roughly $666.1 million of borrowing capacity available under the revolver as of March 31, 2026. The debt picture remains meaningful: the Company notes a ratio of total net debt to EBITDA of about 4.3x at quarter-end, a level that invites questions about optionality in volatile reimbursement and labor markets.

Outlook and Guidance

Management reaffirmed its 2026 revenue forecast in a band of $3.35 billion to $3.45 billion and an Adjusted EBITDA target of at least $530 million. In other words, the trajectory remains a growth story—but one that calls for discipline in margins and capital deployment. The emphasis on core operations—same-store growth, revenue per case, and cost management—signals a deliberate push to convert top-line momentum into a steadier earnings profile over time.

Executive Commentary

“We are encouraged by our solid start to 2026, with same store revenue growth of 4.4% in line with our Q1 and long-term growth expectations. As we navigate near-term market dynamics, our cost management discipline and continued execution on physician recruitment position us well to meet or exceed our 2026 plan. Our portfolio optimization efforts also remain critical to our long-term strategy as we take steps to better align with our core short-stay surgical operating model.”

— Eric Evans, Chief Executive Officer

“The results we reported today were in line with expectations and reinforce our confidence in reaffirming our guidance for the full year. Through disciplined execution, and a continued focus on improving free cash flow and reducing leverage, we are well-positioned to return the business to consistent growth, while delivering on long-term shareholder value.”

— Dave Doherty, Chief Financial Officer

What It Means for SGRY and Sector Peers

From a plain-vanilla numbers perspective, the quarter is a reminder that revenue growth and margin expansion aren’t always perfectly correlated. Surgery Partners shows a durable demand environment for short-stay surgical services, with volume gains in same-facility operations and a modest lift in per-unit revenue. Yet net loss and a leverage profile around 4.3x EBITDA keep the stock in a zone where investors watch not just the revenue forecast, but the earnings per share trajectory and the cadence of deleveraging.

For peers in ambulatory and specialty surgical services, the message is twofold. First, reaffirming guidance when growth metrics look solid is a signal that management believes the trajectory is sustainable and the current period is more about execution than a structural reset. Second, the emphasis on portfolio optimization and physician recruitment highlights the ongoing arms race in labor and asset mix—an environment where acquisitions, divestitures, and capacity discipline can swing both growth and profitability.

Investors should consider how durable the 4.4% same-store growth and 3.8% revenue-per-case lift are in a reimbursement environment that remains sensitive to payer mix and contract terms. If sector peers can sustain better operating leverage or fund capex via improved free cash flow, the relative valuation of SGRY and its peers could shift toward those who demonstrate a clearer path to positive EPS or a more aggressive, credible plan to de-leverage without throttling growth opportunities.

Risks and Open Questions

The quarter’s net loss raises questions about incremental costs, payer dynamics, and the pace at which the business can convert revenue growth into earnings power. Key questions for investors and sector watchers include: How sustainable is the same-store growth in the face of labor and supply costs? Will the debt/EBITDA multiple compress as the company proceeds with capital deployment or acquisitions? Can the company deliver on its revenue forecast while maintaining a more favorable EPS trajectory?

Conclusion

Surgery Partners’ Q1 2026 results deliver a familiar balance sheet: revenue up, margins under pressure, and a commitment to a 2026 revenue and EBITDA path that requires ongoing discipline. The reaffirmed outlook provides a constructive frame for the rest of the year, but the attention turns to execution—specifically, how the company drives down the net loss per share and nudges leverage lower without sacrificing growth avenues. For peers, the message is clear: growth alone isn’t enough; converting that growth into earnings credibility and capital flexibility will separate the leaders from the rest in a crowded field of ambulatory surgical services.

As always, the stock ticker is a shorthand for a story about pricing power, reimbursement risk, and the pace at which a portfolio can be reweighted to maximize cash flow. For SGRY, the next chapters will hinge on translating a quarter of solid top-line momentum into a sustainable EPS path while keeping revenue forecast guidance intact.